Detection of a soluble form of the leukocyte surface antigen CD48 in plasma and its elevation in patients with lymphoid leukemias and arthritis

被引:48
作者
Smith, GM
Biggs, J
Norris, B
AndersonStewart, P
Ward, R
机构
[1] ST VINCENTS HOSP,CRC BIOPHARMACEUT RES LTD,DARLINGHURST,NSW 2010,AUSTRALIA
[2] ST VINCENTS HOSP,DEPT HAEMATOL,DARLINGHURST,NSW 2010,AUSTRALIA
[3] ST VINCENTS HOSP,DEPT MED ONCOL,DARLINGHURST,NSW 2010,AUSTRALIA
关键词
leukocyte surface antigen; CD48; lymphoid leukemias; arthritis; soluble form; plasma;
D O I
10.1023/A:1027327912204
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Proteins with glycosylphosphatidylinositol (GPI) anchors exhibit a range of activities and some of these proteins exist in both a membrane-associated and a soluble form. CD48 is a 47-kd GPI-linked glycoprotein which is expressed on T and B lymphocytes, monocytes, and many lymphoid malignancies. The biological function of CD48 is unknown. We describe the detection of a soluble form of CD48 in plasma and serum. Its level was quantified by an immunoenzymometric assay (IEMA) specific for soluble CD48. While soluble CD48 was detected in the plasma of healthy individuals (median = 29 ng/ml; range, 15-48 ng/ml), elevated levels were detected in some patients with lymphoproliferative disease (median = 41 ng/ml; range, 9-213 ng/ml), arthritis (median = 42 ng/ml; range, 13-67 ng/ml), and acute EBV infection (174 ng/ml). Soluble CD48 was also detectable in tissue culture supernatants from the Raji lymphoid cell line. The mechanism of CD48 release from cells is unclear. The finding of significant levels of soluble CD48 in plasma and the development of a sensitive IEMA for its measurement will facilitate further studies on its normal function and its role in disease.
引用
收藏
页码:502 / 509
页数:8
相关论文
共 30 条
[1]  
[Anonymous], 1988, Antibodies: A Laboratory Manual
[2]   A SOLUBLE MULTIMERIC RECOMBINANT CD2 PROTEIN IDENTIFIES CD48 AS A LOW AFFINITY LIGAND FOR HUMAN CD2 - DIVERGENCE OF CD2 LIGANDS DURING THE EVOLUTION OF HUMANS AND MICE [J].
ARULANANDAM, ARN ;
MOINGEON, P ;
CONCINO, MF ;
RECNY, MA ;
KATO, K ;
YAGITA, H ;
KOYASU, S ;
REINHERZ, EL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (05) :1439-1450
[3]  
BAZIL V, 1991, J IMMUNOL, V147, P1567
[4]   PHYSIOLOGICAL ENZYMATIC CLEAVAGE OF LEUKOCYTE MEMBRANE MOLECULES [J].
BAZIL, V .
IMMUNOLOGY TODAY, 1995, 16 (03) :135-140
[5]   EPSTEIN-BARR-VIRUS (EBV) INDUCES EXPRESSION OF B-CELL ACTIVATION MARKERS ON INVITRO INFECTION OF EBV-NEGATIVE B-LYMPHOMA CELLS [J].
CALENDER, A ;
BILLAUD, M ;
AUBRY, JP ;
BANCHEREAU, J ;
VUILLAUME, M ;
LENOIR, GM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (22) :8060-8064
[6]   CLONING OF DECAY-ACCELERATING FACTOR SUGGESTS NOVEL USE OF SPLICING TO GENERATE 2 PROTEINS [J].
CARAS, IW ;
DAVITZ, MA ;
RHEE, L ;
WEDDELL, G ;
MARTIN, DW ;
NUSSENZWEIG, V .
NATURE, 1987, 325 (6104) :545-549
[7]  
DUKE O, 1982, CLIN EXP IMMUNOL, V49, P22
[8]   CHARACTERIZATION OF THE EPSTEIN-BARR VIRUS-INDUCIBLE GENE ENCODING THE HUMAN-LEUKOCYTE ADHESION AND ACTIVATION ANTIGEN BLAST-1 (CD48) [J].
FISHER, RC ;
THORLEYLAWSON, DA .
MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (03) :1614-1623
[9]  
FLEIT HB, 1992, BLOOD, V79, P2721
[10]  
GOLD P, 1978, CANCER, V42, P1399, DOI 10.1002/1097-0142(197809)42:3+<1399::AID-CNCR2820420803>3.0.CO